NewsSource: EClinCloud

Congratulations! EClinCloud EDC Supports Marketing Approval of Core Medical's CorVad Interventional Left Ventricular Assist System

2 min readEClinCloud Editorial Team
News header image: Congratulations! EClinCloud EDC supports the marketing approval of Core Medical's CorVad interventional left ventricular assist system

Source: EClinCloud. Author: EClinCloud.

Congrat-

ulations

Recently, Shenzhen Core Medical Technology Co., Ltd. ("Core Medical") announced that China's first interventional left ventricular assist system, the CorVad interventional left ventricular assist device and interventional left ventricular assist catheter pump kit, has officially received NMPA marketing approval. The system uses miniaturized axial motor technology for short-term left ventricular support, marking a domestic first in technology and filling a technical gap in interventional cardiac assist devices in China. This marketing approval of the CorVad interventional left ventricular assist system will lead China's ventricular assist technology into a new "minimally invasive and high-efficiency" stage.

As a long-term partner of Core Medical, the EClinCloud EDC system provided ongoing professional support for this interventional medical device project, supporting efficient data capture and management in the multi-center clinical study, ensuring that study processes complied with regulatory requirements, and ensuring data completeness and reliability.

EClinCloud extends its sincere congratulations to Core Medical on this major achievement! Going forward, EClinCloud will continue working with its partners to empower clinical research with technology, accelerate the translation of innovative achievements, and benefit more patients.




The following content is reposted from: Core Medical's official WeChat account


CorVad: China's First Approved Interventional Left Ventricular Assist System

Used together, the CorVad interventional left ventricular assist catheter pump kit and interventional left ventricular assist device are inserted via a minimally invasive percutaneous interventional approach and can be used in high-risk percutaneous coronary intervention (PCI) to provide minimally invasive and convenient left ventricular support for adult patients with severe coronary artery disease, reduced left ventricular ejection fraction, and hemodynamic stability. CorVad uses miniaturized built-in axial motor technology; the system can effectively offload the left ventricular workload, pump blood into the aorta, rapidly improve systemic organ perfusion, and improve procedural safety.






About EClinCloud


EClinCloud is a leading AI company in the clinical research industry. Driven by AI, it has built an integrated clinical intelligence cloud platform and endpoint assessment technologies to provide global pharmaceutical companies and research institutions with technology products including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, as well as scale management, linguistic validation, rater training, and data quality analysis services, building efficient and precise digital solutions and relying on AI prediction models and an intelligent data platform to dynamically evaluate and help improve the success rate of drug clinical trials, helping shorten drug and device R&D cycles and benefiting patients.







Article image



Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.